Results 71 to 80 of about 75,684 (261)

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

In vitro fertilization: a cross-sectional analysis of 58 US insurance companies. [PDF]

J Assist Reprod Genet, 2023
Ha M, Drees A, Myers M, Finkelstein ER, Dandulakis M, Reindorf M, Roque DM, Beall SA, Slezak S, Rasko YM.   +9 more
europepmc   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

A systematic literature review on sustainability issues along the value chain in insurance companies and pension funds. [PDF]

Eur Actuar J, 2023
Aburto Barrera LI, Wagner J.
europepmc   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

British Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J. Nutt, Martina Di Simplicio   +3 more
wiley   +1 more source

Environmental Pollution Liability Insurance Pricing and the Solvency of Insurance Companies in China: Based on the Black-Scholes Model. [PDF]

Int J Environ Res Public Health, 2023
Chen S, Yang J.
europepmc   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source

Insurance Coverage of Dermabrasion and Chemical Peel Procedures: A Critical Analysis of 58 American Insurance Companies. [PDF]

Cureus, 2022
Ha M, Finkelstein ER, Wieland M, Qadri A, Brown M, Ejimogu J, Rasko YM.   +6 more
europepmc   +1 more source

Environmental impact of antidepressants: Is a new prescription framework possible?

British Journal of Clinical Pharmacology, EarlyView.
Aims Antidepressants such as venlafaxine and sertraline pose high risks to water ecosystems. As depressive disorders and other mental health conditions become increasingly prevalent worldwide, prescription and environmental presence of these pharmaceuticals continue to rise. This study explores the practical viability of a new framework for prescribing
Matilde Bianconi, Valentina Giunchi, Michael Thiede, Elisa Sangiorgi, Marco Menchetti, Elisabetta Poluzzi   +5 more
wiley   +1 more source

Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial Insurance Companies. [PDF]

J Psoriasis Psoriatic Arthritis, 2022
Learned C, Alsukait S, Fiumara KR, Ortega M, Chambers JD, Rosmarin D.   +5 more
europepmc   +1 more source